March 19, 2021 09:30 AM EDTUpdated 01:37 PM

Gone away are the bluebird execs as COO, CMO both leave the nest; Mike Nally is latest major figure to move on from Merck

Alex Hoffman

Senior Editor

Kathy Wong

Editor

→ As bluebird bio’s regulatory concerns swell yet again by pressing the pause button for LentiGlobin a month ago, Joanne Smith-Farrell won’t be around to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gone away are the bluebird execs as COO, CMO both leave the nest; Mike Nally is latest major figure to move on from Merck

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Gone away are the blue­bird ex­ecs as COO, CMO both leave the nest; Mike Nal­ly is lat­est ma­jor fig­ure to move on from Mer­ck

Senior Editor

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Gone away are the bluebird execs as COO, CMO both leave the nest; Mike Nally is latest major figure to move on from Merck